1.How significantly will CNPV influence your organization's planning for regulatory submission strategies, aiming for the accelerated 1–2 month review?

Very Significantly (A major shift in R&D and manufacturing planning)

Significantly (Will prioritize qualifying products)

Moderately (Minor adjustments, but not a primary driver)

Minimally (Little to no impact)

Not Applicable / Unsure

2.How likely is your organization to invest in new US facility capacity specifically to increase the chances of qualifying for accelerated FDA review?

Very likely

Somewhat likely

Neutral/Depends on the market

Somewhat unlikely

Very unlikely

3.How transparent and predictable do you find FDA's current process for selecting national priority voucher recipients?

Very transparent and predictable

Somewhat transparent and predictable

Neutral

Vague and unpredictable

Highly vague, potentially leading to future litigation

4.If your company received a priority voucher, would it be ready for market launch in 2 months?

Yes, highly likely

Somewhat likely

Somewhat unlikely

No, highly unlikely

5.Which drug development process would be easiest for your organization to scale up quickly?

Chemistry, manufacturing, and controls (CMC)

Compliance/Regulatory

Supply chain

Commercialization

Post-market safety monitoring

Other (please specify)

6.Can a thorough FDA review assessing safety and quality be completed in 1-2 months?

Not at all

Probably not

Maybe/Unsure

Probably

Definitely